WallStSmart

Fulgent Genetics Inc (FLGT)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 20450% more annual revenue ($66.57B vs $323.93M). MRK leads profitability with a 4.8% profit margin vs -26.1%. FLGT appears more attractively valued with a PEG of 1.32. FLGT earns a higher WallStSmart Score of 42/100 (D).

FLGT

Hold

42

out of 100

Grade: D

Growth: 2.7Profit: 2.0Value: 7.0Quality: 9.0
Piotroski: 5/9Altman Z: 7.36

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FLGTUndervalued (+54.4%)

Margin of Safety

+54.4%

Fair Value

$50.41

Current Price

$21.68

$28.73 discount

UndervaluedFair: $50.41Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$83.64

Current Price

$146.35

$62.71 premium

UndervaluedFair: $83.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLGT3 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.3610/10

Safe zone — low bankruptcy risk

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$360.08B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

FLGT4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Market CapQuality
$553.88M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-8.4%2/10

ROE of -8.4% — below average capital efficiency

EPS GrowthGrowth
-98.6%2/10

Earnings declined 98.6%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : FLGT

The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : FLGT

The primary concerns for FLGT are Revenue Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

FLGT profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

FLGT carries more volatility with a beta of 0.93 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

FLGT scores higher overall (42/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fulgent Genetics Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?